Emphysema and RENEW

Emphysema, a form of COPD, is characterized by alveolar destruction, loss of the lung’s natural elastic properties, and increased lung volume, which make breathing difficult.

Traditional treatment options include smoking cessation, drug therapy (inhaled steroids, bronchodilators and antibiotics), supplemental oxygen and pulmonary rehabilitation (breathing exercises). As emphysema is a progressive disease, eventually these standard treatments will no longer relieve the patient’s symptoms. 

BTG’s flagship Interventional Pulmonology product, the PneumRx® Coils are minimally invasive implants intended to improve exercise capacity, lung function and quality of life in patients with severe emphysema. 

In October of 2014, enrollment for the 315-subject Coil pivotal trial at 30 sites in the US and Europe was completed. RENEW is a randomized controlled study with a primary endpoint of improvement in 6 Minute Walk Test from baseline to 12 months, comparing PneumRx Coil treatment subjects to Control subjects. 

If you would like updates about the RENEW study please sign-up here.


The PneumRx® Coils are not approved for commercial sale in the United States, and are restricted by law to investigational use only in the U.S.